Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds expression product or fragment thereof of...
Reexamination Certificate
2007-02-05
2010-06-29
Harris, Alana M (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds expression product or fragment thereof of...
C424S009100, C424S009200, C424S130100, C424S133100, C514S001000, C514S002600, C514S008100
Reexamination Certificate
active
07744880
ABSTRACT:
Provided is a cell growth inhibitor that can be used for treating diseases based on abnormal cell proliferation, and in particular cancer. The cell growth inhibitor contains an anti-glypican 3 antibody as an active ingredient.
REFERENCES:
patent: 6214973 (2001-04-01), Ohtomo et al.
patent: 7361336 (2008-04-01), Bergstein
patent: 7427400 (2008-09-01), Bergstein
patent: 2003/0045691 (2003-03-01), Ono et al.
patent: 2006/0008456 (2006-01-01), Tsuchiya et al.
patent: 2006/0193828 (2006-08-01), Kosaka et al.
patent: 4228089 (1992-10-01), None
patent: 2007238632 (2007-09-01), None
patent: 9633735 (1996-10-01), None
Goldenberg DM and Sharkey RM. Novel radiolabeled antibody conjugates. Oncogene. May 28, 2007;26(25):3734-44.
Johnson and Goldin (Cancer Treatment Reviews 2:1-31, 1975).
Bodey B. et al. Genetically engineered monoclonal antibodies for direct anti-neoplastic treatment and cancer cell specific delivery of chemotherapeutic agents. Curr Pharm Des. Feb. 2000;6(3):261-76.
Carter, Paul. Improving the efficacy of antibody-based cancer therapies. Nature 1: 118-129, Nov. 2001.
Zhu et al. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut 48: 558-564, Apr. 2001.
Powell, Charles A., et al., “Oligonucleotide Microarray Analysis of Lung Adenocarcinoma in Smokers and Nonsmokers Identifies GPC3 as a Potential Lung Tumor Suppressor,”Chest, vol. 121, Suppl. 3, (2002) pp. 6S-7S.
Kim, Han et al., “The Heparan Sulfate ProteoglycanGPC3is a Potential Lung Tumor Suppressor,”American Journal of Respiratory Cell and Molecular Biology, vol. 29, No. 6 (2003), pp. 694-701.
White, GRM et al., “Somatic Glypican 3 (GPC3) mutations in Wilms' tumour,”British Journal of Cancer, vol. 86, No. 12 (2002), pp. 1920-1922.
Veugelers, Mark et al., “The Glypicans: a Family of GPI-Anchored Heparan Sulfate Proteoglycans with a Potential Role in the Control of Cell Division,”Trends in Glycoscience and Glycotechnology, vol. 10, No. 52 (1998), pp. 145-152.
Office Action dated Nov. 11, 2008 issued in corresponding Japanese Patent Application No. 2008-228128.
Chung, Maxey C. M. et al., “Proteomics of Hepatocellular Carcinoma: Present Status and Future Prospects,”Proteomics: Biomedical and Pharmaceutical Applications, (2004), pp. 163-181.
Igaku, Saishin,The Medical Frontline59(6), (2004), pp. 135-143 (with English Translation).
Kurokawa, Yukinori et al., “Molecular features of a non-B, non-C hepatocellular carcinoma; a PCR-array gene expression profiling study,”Journal of Hepatology, 39 (2003), pp. 1004-1012.
Kensa, Rinsho et al.,Clinical Laboratory Investigation, vol. 44, No. 13 (2000), pp. 1649-1657 (with English Translation).
Takels-Horne, Darci et al., “Identification of Differentially Expressed Genes in Hepatocellular Carcinoma and Metastatic Liver Tumors by Oligonucleotide Expression Profiling,”Cancer, vol. 92, No. 2 (2001), pp. 395-405.
Tannapfel, Andrea et al., “Genes involved in hepatocellular carcinoma; deregulation in cell cycling and apoptosis,”Virchows Arch, No. 440 (2002), pp. 345-352.
Honda, Masao et al.,Molecular Medicine, vol. 39, No. 8 (2002), pp. 938-946 (with English Translation).
Kawai, Hiroshi et al.,Pharma Medica, vol. 20, No. 2 (2002), pp. 51-59 (with English Translation).
Honda, Masao et al.Liver Gallbladder and Pancreas, vol. 48, No. 4 (2004), pp. 447-453 (with English Translation).
Goldenberg, Daniel et al., “Analysis of Differentially Expressed Genes in Hepatocellular Carcinoma Using cDNA Arrays,”Molecular Carcinogenesis, vol. 33 (2002), pp. 113-124).
Lage, Hermann et al., “Expression of glypican-related 62kDa antigen is decreased in hepatocellular carcinoma in correspondence to the grade of tumor differentiation,”Virchows Arch, vol. 438 (2001), pp. 567-573.
Office Action issued on Jan. 22, 2008 in connection with U.S. Appl. No. 11/414,676.
Timar, Jozsef et al., “Proteoglycans and tumor progression: Janus-faced molecules with contradictory functions in cancer,”Seminars in Cancer Biology, vol. 12 (2002), pp. 173-186.
“AACR American Association for Cancer Research”, 93rdAnnual Meeting, Apr. 6-10, 2002—San Francisco, California, vol. 43—Mar. 2002.
Pilia, et al., Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome, Giuseppe Pilia, Nature Genetics, vol. 12, Mar. 1996.
Gonzalez, et al., OCI-5/GPC3, a Glypican Encoded by a Gene That Is Mutated in the Simpson-Golabi-Behmel Overgrowth Syndrome, Induces Apoptosis in a Cell Line-specific Manner, Journal of Cell Biology, vol. 141, No. 6, Jun. 15, 1998 1407-1414.
Lage, et al., Cloning and characterization of human cDNAs encoding a protein with high homology to rat intestinal development protein OCI-5, Gene, vol. 188, pp. 151-156, 1997.
Zhu, et al., Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders, Oct. 17, 2000, GUT vol. 48, pp. 558-564.
Chin J. Surg, Mar. 1999, vol. 37, No. 3.
Saikali, et al., Expression of Glypican 3 (GPC3) in Embryonal Tumors, Int. J. Cancer, vol. 89, pp. 418-422 (2000).
Filmus, Glypicans in growth control and cancer, Glycobiology vol. 11 No. 3 pp. 19R-23R, 2001.
Lin, et al., Frequent Silencing of the GPC3 Gene in Ovarian Cancer Cell, Cancer Research 59, 807-810 Feb. 15, 1999.
Hsu et al., Cloning and Expression of a Developmentally Regulated Transcript MXR7 in hepatocellular carcinoma, vol. 57, pp. 5179-5189 (1997).
Mariana Isabel Capurro, et al., Overexpression of Glypican-3 in Human hepatocellular carcinomas determined by immunohistochemistry using a monoclonal antibody, Proceedings of the American Association for Cancer Research, vol. 43, Mar. 2002.
Xu Y, et al. , Developmental Regulation of the Soluble Form of Insulin-like Growth Factor-II/mannose 6-Phosphate Receptor in Human Serum and Amniotic Fluid, Journal of Clinical Endocrinology and Metabolism, Feb. 1998, vol. 83, No. 2, pp. 437-442, XP002959807.
Abstract, Kleeff J.H., et al., Glypican-3 is a Potential Tumore Marker for Hepatocellular Carcinoma, Gastroenterology, W.B. Saunders Company, Philadelphia, U.S., vol. 118, No. 4, Suppl. 2, Part 1, 2000, pp. A261, XP-002959809.
Abstract, Lage H., et al., Glypican-3 Contributes to a Mitoxantrone-Resistant Phenotype in Gastric Carcinoma Cells, Proceedings of the American Association for Cancer Research, vol. 42, Mar. 2001, p. 279, printed from Database Biosis Online! Biosciences Information Service, Philadelphia, PA, U.S., XP001203974.
Herman Lage et al., Expression of a glypican-related 62-kDa antigen is decreased in hepatocellular carcinoma in correspondence to the grade of tumor differentiation, Virchows Arch, vol. 438, pp. 567-573, Feb. 21, 2001.
Freshney, Culture of Animal Cells, A manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p. 4.
Dermer, Biotechnology, 1994, vol. 12, p. 320.
Drexler, Leukemia and Lymphoma, 1993, vol. 9, pp. 1-25.
Zellner et al., Clinical Cancer Research, 1998, vol. 4, pp. 1797-1802.
Embleton et al., Immunology Series, 1984, vol. 23, pp. 181-207.
Hsu, in Tissue Culture Methods and Applications, Kruse and Patterson, Eds, 1973, Academic Press, NY, abstract.
Gura, Science, 1997, vol. 278, pp. 1041-1042.
Jain, Scientific American, 1994, vol. 271, pp. 58-65.
Curti, Critical Review in Oncology and Hematology, 1993 vol. 14, pp. 29-39.
Sanchez-Mejorada et al., Journal Leukocyte Biology, 1998, vol. 63, pp. 521-533.
Huber, PhD Dissertation, Washington University, Dec. 1998.
Johnstone and Thorpe, Immunochemistry in Practice, Blackwell Scientific Publications, Oxford, 1987, p. 49-50.
Queen et al., Proceeding of the National Academy of Science, 1989, vol. 86, pp. 10029-10033.
Reichmann et al., Nature, 1988, vol. 332, pp. 323-327.
Aburatani Hiroyuki
Nakamura Tetsuo
Tsuchiya Masayuki
Chugai Seiyaku Kabushiki Kaisha
Davidson Leslye B.
Davidson Davidson & Kappel LLC
Harris Alana M
LandOfFree
Cell growth inhibitors containing anti-glypican 3 antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cell growth inhibitors containing anti-glypican 3 antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cell growth inhibitors containing anti-glypican 3 antibody will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4199677